Mary Caffrey

Key Takeaways Innovations in cancer care are overshadowed by financial concerns, with high out-of-pocket costs limiting access to essential services.

Listen Key Takeaways The 2023 chemotherapy shortage led to a 60% drop in cisplatin use for head and neck cancer, with costly substitutes increasing treatment expenses.

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.

For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).

Besides Kent Hospital, the Association of Cancer Care Centers worked with Perlmutter Cancer Center at NYU Langone Hospital and Charleston Area Medical Center Vandalia Health in Charleston, West Virginia.

Listen Key Takeaways Charleston AMC joined the ACCC MPN Quality Improvement Program to improve symptom tracking for MPN patients using the MPN-SAF TSS tool.

Key Takeaways Obe-cel, a novel CAR T-cell therapy, shows reduced toxicity and improved persistence due to its unique scFv with intermediate affinity.